Articles: anesthetics.
-
Recent Adv Stud Cardiac Struct Metab · May 1976
Dose-dependent depression of cardiac function and metabolism by inhalation anesthetics in chronically instrumented dogs.
Halothane, methoxyflurane, and enflurane produce dose-dependent depression in ventricular function in the dog. Myocardial blood flow and oxygen consumption are decreased accordingly without evidence of myocardial tissue hypoxia. ⋯ In spite of this depression, myocardial blood flow was unchanged, and the decreased oxygen consumption during high-dose fluroxene was a result of decreased oxygen extraction by the heart. Sympathetic nervous system stimulation produced by fluroxene anesthesia is probably responsible for these effects, but further work is necessary for confirmation of this hypothesis.
-
Southern medical journal · May 1976
Clinical significance of the biotransformation of inhalation anesthetics.
Inhalation anesthetics, a class of drugs formerly believed to be biologically inert, are now recognized to undergo considerable biotransformation. The viscerotoxicity of certain anesthetics on kidney and liver can be explained in terms of metabolism. The entity of "halothane hepatitis" remains mechanistically and diagnostically a mystery, but if it exists, it could be due to abnormalities of biotransformation.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Intradermal study of a new local anaesthetic agent aptocaine.
In a double-blind trial in 28 human volunteers, a new local anaesthetic agent, aptocaine, was compared intradermally at 1, 2 and 3% concentrations with lignocaine 2% and bupivacaine 0.5%. In a second trial in 27 subjects, 1% aptocaine was compared with mepivacaine and prilocaine, both 1, 2 and 3%. In terms of activity as determined by area of anaesthesia, and of duration of action, aptocaine was similar to mepivacaine and more active and long-lasting than lignocaine and prilocaine. ⋯ Duration of action was unaffected by concentration. Aptocaine had marked vasoconstrictor activity, which was maximal at 1%. These local anaesthetic properties suggest that aptocaine merits clinical trials, especially in dentistry.